Janssen announced that the FDA has approved a new 800mg tablet of Prezista (darunavir) for the treatment of HIV-1 in treatment-naïve and treatment-experienced adult patients with no darunavir resistance-associated mutations.

The new strength will allow patients to reduce the number of tablets by half, replacing two 400mg tablets with the one 800mg tablet. Janssen will discontinue the 400mg tablet with the introduction of the new 800mg tablet.

Prezista is a protease inhibitor that selectively inhibits the cleavage of HIV-1 encoded polyproteins which prevents the formation of mature virus particles.

Prezista 800mg tablets are expected to be available shortly. 

For more information call (800) JANSSEN or visit www.prezista.com.